Based on these premises, and in an attempt to identify potentially druggable players of CML progression, we investigated whether advanced‐phase CML, which shares similarities with acute leukemias such as a high degree of genetic instability, might also exhibit loss of function of the SETD2 gene. This evidence concerns the gene SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive.